Baricitinib is a medication traditionally used in the management and treatment of Rheumatoid Arthritis. However, with the recent advent of the COVID-19 global pandemic, several agents have been evaluated for the management of this disease. Baricitinib is in the JAK inhibitor class of medications. This activity reviews the indications, action, and contraindications for the concurrent use of Remdesivir and Baricitinib as valuable agents in the management of COVID-19. This activity will highlight the mechanism of action, adverse event profile, and other key factors like indications and contraindications, dosing, pharmacodynamics, pharmacokinetics, pertinent for members of the interprofessional team in the management of patients with COVID-19 and related conditions

**Objectives:**
- Describe the pathophysiology of COVID-19 and the role of Baricitinb in the management of the disease.
Summarize the epidemiology of Addison disease.
- Identify the indications for using Baricitinib in combination with Remdesivir in hospitalized patients. 
- Review the contraindications and adverse events associated with the use of Baricitinib and Remdesivir. 
- Describe the importance of a multidisciplinary team in the management of COVID-19 leading to safe and effective use of Baricitinib and Remdesivir in hospitalized COVID-19 patients.